budesonide enteric
Selected indexed studies
- Current treatment of IgA nephropathy. (Semin Immunopathol, 2021) [PMID:34495361]
- A case of IgA nephropathy associated with Crohn's disease treated with enteric-coated budesonide. (CEN Case Rep, 2025) [PMID:40447912]
- Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice. (Transpl Int, 2022) [PMID:36311259]
_Worker-drafted node — pending editorial review._
Connections
budesonide enteric is a side effect of
Sources
- Current treatment of IgA nephropathy. (2021) pubmed
- A case of IgA nephropathy associated with Crohn's disease treated with enteric-coated budesonide. (2025) pubmed
- Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice. (2022) pubmed
- Exploring the molecular mechanism of budesonide enteric capsules in the treatment of IgA nephropathy based on bioinformatics. (2025) pubmed
- Enteric-Release Budesonide May Be Useful in the Management of Non-Responsive Celiac Disease. (2021) pubmed
- Actual Use of Budesonide Enteric-Coated Capsules for Crohn's Disease in Japan: Analysis of Health Insurance Big Data. (2025) pubmed
- [Immunomodulatory effects and research progresses of budesonide enteric-coated capsules in IgA nephropathy]. (2025) pubmed
- Corrigendum: Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice. (2022) pubmed
- Enteric and Controlled-Release Budesonide in IgA Nephropathy: Expanding Access While Refining Evidence. (2026) pubmed
- Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. (2005) pubmed